R M Gulick

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi request reprint Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects
    Ronald Swanstrom
    University of North Carolina Center for AIDS Research, University of North Carolina, Chapel Hill 27599, USA
    J Infect Dis 190:886-93. 2004
  2. ncbi request reprint New drugs for HIV therapy
    Roy M Gulick
    Cornell Clinical Trial Unit, Weill Medical College of Cornell University, New York, New York 10024, USA
    AIDS 16:S135-44. 2002
  3. ncbi request reprint Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression
    Roy M Gulick
    Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    AIDS 21:813-23. 2007
  4. ncbi request reprint Antiretroviral management of treatment-naive patients
    Roy M Gulick
    Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
    Infect Dis Clin North Am 21:71-84, viii. 2007
  5. ncbi request reprint Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211
    Roy M Gulick
    Weill Medical College of Cornell University, New York, New York, NY, USA
    J Infect Dis 196:304-12. 2007
  6. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
  7. ncbi request reprint Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection
    Roy M Gulick
    Weill Medical College of Cornell University, New York, USA
    N Engl J Med 350:1850-61. 2004
  8. pmc Antiretroviral treatment 2010: progress and controversies
    Roy M Gulick
    Division of Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10065, USA
    J Acquir Immune Defic Syndr 55:S43-8. 2010
  9. ncbi request reprint New antiretroviral drugs
    R M Gulick
    Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, New York 10024, USA
    Clin Microbiol Infect 9:186-93. 2003
  10. ncbi request reprint Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359
    Roy M Gulick
    Weill Medical College of Cornell University, New York, New York 10021, USA
    J Infect Dis 186:626-33. 2002

Research Grants

  1. Cornell Clinical Trials Unit
    Roy Gulick; Fiscal Year: 2007
  2. Antiretroviral Therapy for HIV-Infected Patients
    Roy Gulick; Fiscal Year: 2007

Detail Information

Publications57

  1. ncbi request reprint Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects
    Ronald Swanstrom
    University of North Carolina Center for AIDS Research, University of North Carolina, Chapel Hill 27599, USA
    J Infect Dis 190:886-93. 2004
    ..This suggests that the prospective evaluation of PSS to identify regimens that maximize decreases in VL to reduce the probability of virologic rebound could improve antiretroviral treatment...
  2. ncbi request reprint New drugs for HIV therapy
    Roy M Gulick
    Cornell Clinical Trial Unit, Weill Medical College of Cornell University, New York, New York 10024, USA
    AIDS 16:S135-44. 2002
  3. ncbi request reprint Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression
    Roy M Gulick
    Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    AIDS 21:813-23. 2007
    ..To compare a quadruple-nucleoside with an efavirenz-containing regimen for treatment of HIV-1 infection...
  4. ncbi request reprint Antiretroviral management of treatment-naive patients
    Roy M Gulick
    Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
    Infect Dis Clin North Am 21:71-84, viii. 2007
    ..The goal of antiretroviral therapy is maximally to suppress viremia, enhance or improve immune function, and prevent clinical progression...
  5. ncbi request reprint Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211
    Roy M Gulick
    Weill Medical College of Cornell University, New York, New York, NY, USA
    J Infect Dis 196:304-12. 2007
    ..Vicriviroc, an investigational CCR5 inhibitor, demonstrated short-term antiretroviral activity in a phase 1 study...
  6. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  7. ncbi request reprint Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection
    Roy M Gulick
    Weill Medical College of Cornell University, New York, USA
    N Engl J Med 350:1850-61. 2004
    ....
  8. pmc Antiretroviral treatment 2010: progress and controversies
    Roy M Gulick
    Division of Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10065, USA
    J Acquir Immune Defic Syndr 55:S43-8. 2010
    ..Further research will help optimize current antiretroviral treatments and strategies...
  9. ncbi request reprint New antiretroviral drugs
    R M Gulick
    Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, New York 10024, USA
    Clin Microbiol Infect 9:186-93. 2003
    ..Investigational HIV integrase inhibitors include S-1360. Continued progress in the treatment of HIV disease will result from the development of new antiretroviral drugs...
  10. ncbi request reprint Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359
    Roy M Gulick
    Weill Medical College of Cornell University, New York, New York 10021, USA
    J Infect Dis 186:626-33. 2002
    ..These results show that some patients who experience treatment failure can demonstrate durable virologic and immunologic responses with salvage antiretroviral regimens...
  11. ncbi request reprint Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial
    Roy M Gulick
    Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY, USA
    JAMA 296:769-81. 2006
    ..Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen...
  12. ncbi request reprint 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
    R M Gulick
    Weill Medical College of Cornell University, New York, New York, USA
    Ann Intern Med 133:35-9. 2000
    ..Antiretroviral regimens containing HIV protease inhibitors suppress viremia in HIV-infected patients, but the durability of this effect is not known...
  13. ncbi request reprint Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359
    R M Gulick
    Cornell Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Dept of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Infect Dis 182:1375-84. 2000
    ..18%; P=.002). Overall, one-third of patients who experienced virologic failure on an indinavir-containing regimen suppressed virus load levels while they were taking a new salvage regimen...
  14. ncbi request reprint Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373
    R M Gulick
    Weill Medical College of Cornell University and New York University School of Medicine, Cornell Clinical Trials Unit, New York, NY 10021, USA
    J Infect Dis 183:715-21. 2001
    ..7; P=.0012). In this study, most subjects who had taken amprenavir-based regimens and who changed to a 4-drug regimen achieved subsequent durable virologic suppression...
  15. ncbi request reprint Structured treatment interruption in patients infected with HIV: a new approach to therapy
    Roy M Gulick
    Cornell Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, New York 10021, USA
    Drugs 62:245-53. 2002
    ..Currently, STI cannot be recommended as part of routine clinical care. Prospective studies are needed to assess the risks and benefits of this strategy in all clinical settings...
  16. ncbi request reprint Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up
    R M Gulick
    Department of Medicine, New York University School of Medicine, New York, USA
    JAMA 280:35-41. 1998
    ..Combination antiretroviral therapy can markedly suppress human immunodeficiency virus (HIV) replication but the duration of HIV suppression varies among patients...
  17. ncbi request reprint Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial
    Scott M Hammer
    Division of Infectious Diseases, Department of Medicien, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
    JAMA 288:169-80. 2002
    ..Management of antiretroviral treatment failure in patients receiving protease inhibitor (PI)-containing regimens is a therapeutic challenge...
  18. ncbi request reprint Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team
    R L Murphy
    Division of Infectious Diseases, Northwestern University Medical School, Illinois, Chicago, IL 60611, USA
    J Infect Dis 179:808-16. 1999
    ..04 log10 copies/mL, and 17 (63%) of 27 evaluable subjects had <500 HIV RNA copies/mL. Treatment with amprenavir, zidovudine, and lamivudine together reduced the levels of HIV RNA significantly more than did amprenavir monotherapy...
  19. ncbi request reprint Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine
    Roy M Gulick
    Weill Medical College of Cornell University, New York, USA
    AIDS 17:2345-9. 2003
    ..To assess virological and immunological responses and toxicity in subjects receiving combination antiretroviral therapy...
  20. ncbi request reprint The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)
    Arlene S Pereira
    Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA
    J Infect Dis 186:198-204. 2002
    ..The antiretroviral effect of APV monotherapy was related to APV concentrations...
  21. ncbi request reprint Switching antiretroviral therapy: why, when and how
    Timothy Wilkin
    Weill Medical College, Cornell University, New York, USA
    IAPAC Mon 12:220-9. 2006
  22. ncbi request reprint Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients
    Nathalie C Casau
    Division of International Medicine and Infectious Diseases, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    J Acquir Immune Defic Syndr 32:494-8. 2003
    ..05). Some HIV-infected patients concurrently treated with lopinavir/ritonavir and a third PI have viral suppression; many eventually discontinue therapy because of toxicity or virologic failure...
  23. ncbi request reprint Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease
    B H Lerner
    Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Ann Intern Med 129:573-8. 1998
    ..Encouraging the active participation of HIV-positive persons in their own treatment will help avoid judgmental and inaccurate assessments of patient behavior and may help patients take medications more successfully...
  24. ncbi request reprint Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095
    Bruce R Schackman
    Department of Public Health, Weill Medical College, New York, NY 10021, USA
    J Acquir Immune Defic Syndr 46:547-54. 2007
    ..We rigorously examined associations over time among race, virologic failure, 4 self-reported adherence metrics, and quality of life (QOL)...
  25. doi request reprint When to start antiretroviral therapy?
    Timothy J Wilkin
    Division of International Medicine and Infectious Diseases, Weill Cornell Medical College, New York, New York 10011, USA
    Clin Infect Dis 47:1580-6. 2008
    ..Additional cohort and clinical trials data are needed...
  26. ncbi request reprint Antiretroviral therapy: when and what to start-- an American perspective
    Timothy J Wilkin
    Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
    Curr HIV/AIDS Rep 1:59-67. 2004
    ....
  27. pmc Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients
    Timothy J Wilkin
    Division of Infectious Diseases Weill Cornell Medical College, New York, NY, USA
    J Acquir Immune Defic Syndr 54:470-6. 2010
    ..Vicriviroc, an investigational CCR5 antagonist, demonstrated short-term safety and antiretroviral activity...
  28. ncbi request reprint Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV
    Joseph J Eron
    Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Infect Dis 189:1075-83. 2004
    ..43 to -0.05 log(10) copies/mL) for the lowest dose to -1.96 log(10) copies/mL (95% CI, -2.02 to -1.37 copies/mL) for the highest dose. These results indicate that T-1249 is a potent new therapeutic agent for HIV-1 infection...
  29. ncbi request reprint HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211
    Timothy J Wilkin
    Division of International Medicine and Infectious Diseases, Weill Cornell Medical College, New York, NY, USA
    Clin Infect Dis 44:591-5. 2007
    ..Chemokine coreceptor use impacts both the natural history of human immunodeficiency virus type 1 (HIV-1) disease and the potential use of a new class of antiretroviral agents, the CCR5 inhibitors...
  30. pmc The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients
    Timothy J Wilkin
    Division of Infectious Diseases, Weill Cornell Medical College, New York, New York 10011, USA
    HIV Clin Trials 11:351-8. 2010
    ..This observation supports further evaluation of CCR5 antagonists in patients with discordant immunologic and virologic responses to ART...
  31. pmc Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity
    Timothy J Wilkin
    Division of Infectious Disease, Weill Cornell Medical College, New York, New York 10011, USA
    Clin Infect Dis 52:925-8. 2011
    ..Nine percent to 26% of patients with CCR5-tropic virus by the original Trofile assay had CXCR4-using virus by TF-ES. Lower CD4 cell counts were associated with CXCR4-using virus in all cohorts...
  32. doi request reprint Raltegravir: the first HIV type 1 integrase inhibitor
    Charles Hicks
    Duke University Medical Center, Weill Medical College of Cornell University, Durham, North Carolina 27710, USA
    Clin Infect Dis 48:931-9. 2009
    ..As an antiretroviral drug with a novel mechanism of action, raltegravir is an important advancement in HIV-1 treatment options...
  33. ncbi request reprint New antiretroviral agents for the treatment of HIV infection
    Kristen Marks
    Weill Medical College of Cornell University, Cornell Clinical Trials Unit, New York, NY 10021, USA
    Curr HIV/AIDS Rep 1:82-8. 2004
    ..Continued improvement in the treatment of HIV infection will result from the availability of convenient, well-tolerated, and affordable drugs with potent and durable antiretroviral activity...
  34. ncbi request reprint Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus
    Kristen M Marks
    Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Infect Dis 192:1943-9. 2005
    ..The prevalence and significance of steatosis in patients coinfected with human immunodeficiency virus (HIV) and HCV are not well characterized...
  35. ncbi request reprint Case-control study of diabetes mellitus in HIV-infected patients
    Cecilia Yoon
    Department of Medicine, Weill Medical College, Cornell University, New York, NY 10011, USA
    J Acquir Immune Defic Syndr 37:1464-9. 2004
    ..Diabetes mellitus (DM) is more prevalent among patients with HIV infection. Besides protease inhibitors (PIs), other factors may contribute to the development of DM...
  36. ncbi request reprint Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals
    David B Clifford
    Washington University School of Medicine, Neurology Department, St Louis, Missouri 63110, USA
    Ann Intern Med 143:714-21. 2005
    ..Efavirenz is a commonly used antiretroviral drug that causes neurologic side effects in more than 50% of patients...
  37. doi request reprint Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects
    Daniel R Kuritzkes
    Brigham and Women s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
    J Infect Dis 197:867-70. 2008
    ..27 [95% confidence interval], 1.15-4.49; P = .018). These results support resistance testing before starting antiretroviral therapy...
  38. doi request reprint Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 197:1006-10. 2008
    ..There were no significant differences among subgroups with respect to treatment responses. These results demonstrate the potency of efavirenz-containing regimens across a spectrum of pretreatment VLs and CD4 counts...
  39. pmc Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection
    Jeffrey A Anderson
    UNC Center for AIDS Research, University of North Carolina, Chapel Hill, North Carolina 27759, USA
    AIDS Res Hum Retroviruses 24:685-94. 2008
    ..These data indicate that GSS may be a useful tool in selecting drug regimens in HIV-1-infected subjects to maximize virologic response and improve treatment outcomes...
  40. ncbi request reprint Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study
    Charles Hicks
    Duke University Medical Center, Durham, North Carolina, 27710, USA
    AIDS 18:775-9. 2004
    ..Results of long-term therapy with LPV/r-based regimens have not been previously reported. This study describes the 4-year (204-week) safety and antiretroviral activity of LPV/r-based treatment in antiretroviral-naive individuals...
  41. ncbi request reprint Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359
    Courtney V Fletcher
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Infect Dis 189:1176-84. 2004
    ..42%; adjusted odds ratio, 0.43). In this study, a greater proportion of females had HIV RNA levels </=500 copies/mL than did males, which can be attributed to higher concentrations of saquinavir in females than in males...
  42. ncbi request reprint Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients
    Constance A Benson
    Department of Medicine, University of Colorado Health Sciences Center, 4200 E 9th Avenue, B 168, Denver, CO 80262, USA
    J Infect Dis 185:599-607. 2002
    ..Mean CD4 cell counts increased by 125 cells/muL. Three patients discontinued therapy for drug-related adverse events...
  43. ncbi request reprint Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy
    Ole Kirk
    Copenhagen HIV Programme 044, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
    Antivir Ther 7:271-81. 2002
    ..To compare two analytic approaches to assess the virological effect of HAART according to the intention-to-treat (ITT) principle...
  44. doi request reprint Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients
    Robert L Murphy
    Northwestern University, Chicago, Illinois, USA
    HIV Clin Trials 9:1-10. 2008
    ..Evaluate efficacy and tolerability of lopinavir/ritonavir (LPV/r) plus stavudine and lamivudine long term in antiretroviral-naïve patients...
  45. ncbi request reprint Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study
    David W Haas
    Program for Human Genetics, Vanderbilt University School of Medicine, 345 24th Avenue North, Nashville, TN 37203, USA
    AIDS 18:2391-400. 2004
    ..Efavirenz is metabolized by cytochrome P4502B6 (CYP2B6). We investigated whether polymorphisms in CYP2B6, CYP3A4, CYP3A5, and MDR1 were associated with efavirenz central nervous system side effects and pharmacokinetics...
  46. ncbi request reprint A comparison of three initial antiretroviral AIDS regimens
    Heather J Ribaudo
    N Engl J Med 357:1056-7. 2007
  47. ncbi request reprint Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study
    Heather J Ribaudo
    Statistical Data Analysis Center, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 42:401-7. 2006
    ..Lower plasma efavirenz clearance is associated with a cytochrome P450 2B6 gene (CYP2B6) polymorphism (516G-->T) that is more frequent among African American individuals than among European American individuals...
  48. ncbi request reprint Adherence to antiretroviral therapy: how much is enough?
    Roy M Gulick
    Clin Infect Dis 43:942-4. 2006
  49. ncbi request reprint A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086
    Constance A Benson
    University of California, San Diego School of Medicine, San Diego, CA 92103, USA
    J Infect Dis 194:1309-18. 2006
    ..The role of structured treatment interruption (STI) before optimized antiretroviral therapy (ART) in patients with drug-resistant human immunodeficiency virus type 1 (HIV-1) is uncertain...
  50. ncbi request reprint The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects
    David B Clifford
    Washington University School of Medicine, St Louis, MO 63110, USA
    AIDS 19:S64-71. 2005
    ....
  51. ncbi request reprint Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)
    Cecilia M Shikuma
    Hawaii AIDS Clinical Research Program, John A Burns School of Medicine, University of Hawaii at Manoa, Manoa Leihi Hospital, 3675 Kilauea Avenue, Honolulu, HI 96816, USA
    J Acquir Immune Defic Syndr 44:540-50. 2007
    ..To assess metabolic changes after initiation of protease inhibitor (PI)-sparing regimens in antiretroviral-naive patients...
  52. ncbi request reprint Design issues in initial HIV-treatment trials: focus on ACTG A5095
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, USA
    Antivir Ther 11:751-60. 2006
    ..We also hope to inform the field regarding issues in choosing composite versus virological endpoints as well as other key considerations in trial design and monitoring...
  53. ncbi request reprint Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s
    Daniel R Kuritzkes
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, Cambridge, MA 02139, USA
    J Infect Dis 195:1169-76. 2007
    ..We sought to compare clearance rates of plasma human immunodeficiency virus type 1 (HIV-1) RNA in men and women starting triple-nucleoside-based versus efavirenz (EFV)-based regimens...
  54. ncbi request reprint Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359
    Courtney V Fletcher
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Acquir Immune Defic Syndr 40:301-6. 2005
    ..Self-reported adherence and saquinavir AUC were significant predictors of virologic response, in this evaluation. These findings provide insight into methods of assessing and improving adherence to antiretroviral regimens...
  55. ncbi request reprint Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359
    Richard H Haubrich
    University of California San Diego, San Diego, California 92103, USA
    HIV Clin Trials 8:63-7. 2007
    ....
  56. ncbi request reprint Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study)
    Andrew R Zolopa
    Stanford University School of Medicine, Stanford, CA 94305 5107, USA
    Clin Infect Dis 41:92-9. 2005
    ..We sought to determine how much agreement exists within a group of experts in the interpretation of complex genotypes...
  57. pmc In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject
    Athe M N Tsibris
    Massachusetts General Hospital, Boston, Massachusetts, USA
    J Virol 82:8210-4. 2008
    ..Pretreatment V3 loop sequences reemerged following VCV discontinuation, implying that VCV resistance has associated fitness costs...

Research Grants4

  1. Cornell Clinical Trials Unit
    Roy Gulick; Fiscal Year: 2007
    ..A major focus of the Cornell unit is community outreach and education and the Cornell Community Advisory Board is active in representing our diverse community. ADMINISTRATIVE COMPONENT: ..
  2. Antiretroviral Therapy for HIV-Infected Patients
    Roy Gulick; Fiscal Year: 2007
    ..Effective mentodng and training will help develop future clinical investigators. ..